Delayed Chemotherapy-Induced Nausea and Vomiting in autologous hematopoietic cell transplant patients: an exploratory analysis by Gonella, S & DI GIULIO, Paola
This full text was downloaded from iris - AperTO: https://iris.unito.it/
iris - AperTO
University of Turin’s Institutional Research Information System and Open Access Institutional Repository
This is the author's final version of the contribution published as:
Gonella S; Di Giulio P.. Delayed Chemotherapy-Induced Nausea and
Vomiting in autologous hematopoietic cell transplant patients: an exploratory
analysis. TUMORI. 19 (4) pp: 438-443.
DOI: 0.5301/tj.5000296
When citing, please refer to the published version.
Link to this full text:
http://hdl.handle.net/2318/1508803
  
 
1 
Title of the paper 
Delayed Chemotherapy-Induced Nausea and Vomiting in autologous hematopoietic 
cell transplant patients: an exploratory analysis   
 
Running title 
An exploratory analysis on delayed CINV  
 
Authors 
Silvia Gonella, MSc, RN1; Paola Di Giulio, Associate Professor of Nursing, MSc, 
RN1.  
 
1Department of Public Health and Paediatric Sciences, University of Torino, Torino, 
Italy  
 
Correspondence  
Silvia Gonella, Department of Public Health and Pediatric Sciences, University of 
Torino, Via Santena 5 bis, 
10126 Torino, Italy   
T +39 339 8409093 
F +39 011 6705871 
silviago87@libero.it 
 
 
Conflict of interest The authors have no funding or conflict of interest to disclose 
 
  
 
2 
Abstract 
Purpose: Delayed chemotherapy-induced nausea and vomiting (CINV) continues to 
be a problem in patients undergoing a hematopoietic cell transplant (HCT) despite 
progress in antiemetic prophylaxis. The study described the clinical course of nausea 
and vomiting (NV) and retching over the 5-days following an autologous-HCT in the 
transplant setting. Methods: This longitudinal observational study is an exploratory 
analysis of data from a trial that assessed the efficacy of aroma in preventing NV 
related to dimethyl sulfoxide in 69 autologous-HCT patients undergoing high 
emetogenic chemotherapy (HEC, n = 56) or moderate emetogenic chemotherapy 
(MEC, n = 13). Results: Nausea started to increase on the second day after 
reinfusion, with a peak between 72 and 96 hours, and decreased on the fifth day. 
The pattern for vomiting was similar, while retching episodes remained unchanged 
after the third day following transplant. Nausea and emesis were observed in 73% (n 
= 41) and 64% (n = 36) of HEC patients, respectively, and in 85% (n = 11) and 62% 
(n = 8) of MEC patients, respectively. Conclusion: Uncontrolled delayed CINV is still 
a challenge for autologous-HCT patients. Nausea, vomiting and retching are three 
different symptoms that should be assessed and managed separately in the routine 
clinical practice.  
Key words: Hematopoietic Stem Cell Transplantation; Nausea; Vomiting.  
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Introduction 
The occurrence of chemotherapy-induced nausea and vomiting (CINV) is usually 
biphasic, consisting of the first 24 hours following chemotherapy (acute CINV) and 
lasting up to 5-7 days after chemotherapy (delayed CINV) (1). Delayed CINV 
continues to be an important problem in patients that receive moderate (MEC) to 
high (HEC) emetogenic chemotherapy.  
Lopez-Jimenez et colleagues (2) found that 90% of all patients undergoing 
autologous or allogeneic hematopoietic cell transplant (HCT) and 55% of acute 
leukaemia patients treated with multiple-day chemotherapy complained of nausea. In 
the five days following treatment, approximately 35% of patients with leukaemia and 
only 10% of HCT patients were completely protected from nausea and vomiting 
without rescue therapy (2). Our recent randomised controlled trial (3), exploring the 
efficacy of aroma in preventing nausea and vomiting (NV) related to dimethyl 
sulfoxide (DMSO) in 69 autologous HCT (auto-HCT) patients undergoing high 
myeloablative conditioning regimens, found delayed NV in 90% patients. 
 In spite of the availability of new drugs the problem is still unresolved. Novel 
classes of antiemetics (e.g., palonosetron, a second-generation 5-
hydroxytryptamine-3 receptor antagonist (5HT3-RA) and aprepitant, a neurokinin-1 
receptor antagonist (NK1-RA)) improved control of CINV but mainly of emesis and in 
the acute phase. Schwartzberg and colleagues (4) showed that three quarter of 
HCT-patients complained of delayed nausea although the use of second generation 
5HT3-RA. A study on 1143 patients receiving HEC found that over 60% of patients 
randomised to palonosetron suffered from delayed nausea and almost 40% reported 
delayed emesis compared to those treated with granisetron plus dexamethasone (5). 
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 A trial (6) on the superiority of aprepitant (n = 260) versus standard therapy (n = 
260) in patients receiving high-dose cisplatin, showed that patients who received 
aprepitant had similar acute and delayed nausea compared to those undergoing 
standard therapy (27.7% vs 30.9% and 49% vs 52.3%, respectively). Patients with 
emesis were significantly lower in the aprepitant compared with the standard therapy 
group, both in the acute and delayed phases (10% vs 20.7% and 19.2% vs 41.2%, 
respectively). A phase III trial also found that 47% (n = 122) and 28% (n = 73) of 
patients randomised to aprepitant still complained of delayed nausea and vomiting 
(7).  
 The problem is further complicated by a lack of specific guidelines for 
haematological patients and by a variable compliance with the available guidelines. 
A recent prospective observational study in eight European countries (8) in 991 
chemotherapy-naïve adults undergoing HEC or MEC showed low adherence to 
antiemetic guidelines, varying between the acute and delayed phases, and 
emetogenity of regimens. A guideline consistent CINV prophylaxis (GCCP) was 
implemented for 55% and 46% patients during the acute and delayed phases, 
respectively, and was lower in HEC compared to MEC regimens (21, 7.3% vs 133, 
46.3%), both in the acute and delayed phase. Other studies (9) showed an 11% 
adherence to the Multinational Association of Supportive Care in Cancer (MASCC) 
guidelines (10) for the prevention of delayed CINV in 75 HEC patients, with frequent 
omissions of corticosteroids and an overuse of 5HT3-RAs. Poor adherence to 
dexamethasone and NK1-RA continues to be a widespread problem (11-13).  
 However, adherence to antiemetic guidelines improved the control of CINV. In two 
studies (8,13) GCCP-treated patients reported less delayed CINV than those without 
the recommended prophylaxis. Gilmore and colleagues found patients receiving a 
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GCCP to have a 31% increase in delayed CINV protection compared to those 
without the recommended prophylaxis (adjusted odds ratio [OR] = 1.31, 95% CI 
1.07-1.69, p = 0.037). A similar although not statistically significant advantage was 
found by Aapro (OR = 1.27, 95% CI 0.92-1.75, p = 0.142) (8). 
 Despite many studies (4,14) explored the incidence of acute and delayed CINV 
associated with high dose conditioning regimens for HCT, none described their daily 
clinical course in a transplant setting. This study aims to describe the course of 
nausea, vomiting and retching over the five days following auto-HCT.  
 
Methods 
Study design 
Longitudinal observational exploratory analysis of data derived from a multicentre 
RCT that was conducted between June 2012 and January 2013 (3). The patient data 
were analysed as a merged prospective cohort. The study was approved by the 
ethics committee. 
 
Primary study 
A randomised, three-arm, open-label trial in four Italian large bone marrow transplant 
centres was conducted. The aim of the primary study was to assess the 
effectiveness of orange aroma in preventing NV related to DMSO in 69 auto-HCT 
patients. DMSO is the cryopreservative used to store hematopoietic cells and is 
indeed associated with frequent NV partly related to its characteristic garlic-like 
breath (15). The smell and flavor of orange had been hypothesized to reduce the 
patient’s perception of its unpleasant odor (16,17). Patients were randomised to 
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orange (n = 23) or non-citrus ice lollies (n = 21) and routine treatment (deep breaths, 
n = 25).  
 Data on NV and retching were collected up to 5 days after infusion. Patients 
completed 6-day daily diaries beginning on the transplant day and continuing until 
day 5, reporting their nausea intensity every 4 hours (Numeric Rating Scale [NRS] 0-
100) along with vomiting and retching (VR) episodes.  
 
Exploratory secondary analysis  
The aim of this exploratory secondary analysis was to describe the course of 
nausea, vomiting and retching over the five days following auto-HCT, regardless the 
treatment received (i.e., orange ice lollies, non-citrus ice lollies, deep breaths) in the 
primary study. Patients’ data were analysed as a merged prospective cohort 
controlling for the treatment.    
 
Data collection 
Data on NV and retching were collected up to 5 days after infusion, meaning an 
observation period from 2 to 7 days after the end of the conditioning regimen, based 
only on chemotherapy in this group of patients. The transplant generally takes place 
24 hours after the end of chemotherapy (18).     
 Antiemetic prophylaxis was collected from clinical records. Nausea was 
considered absent if <5, controlled between 5-25 and uncontrolled if >25 (2). Distinct 
VR episodes were separated by at least 1 minute. VR were considered controlled if 
there were ≤2 episodes/day (vomiting or retching) (2).  
 The emetogenic potential of each drug was defined according to the MASCC 
guidelines (10).  
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 The emetogenicity of the combined regimens was defined as follows: not 
increased by the minimal emetogenic agent and increased by one level from the low 
emetogenic agent compared to the most emetogenic agent administered; the 
moderately and highly emetogenic agent increased the emetogenicity of each drug 
by one level (19). 
 According to MASCC guidelines (10), the following regimens are recommended in 
the delayed phase: dexamethasone days 2-4 plus aprepitant days 2-3 after 
chemotherapy for HEC and aprepitant, dexamethasone or a 5HT3RA days 2-3 after 
chemotherapy for MEC.  
Adherence to the recommended prophylaxis was scored as yes/no. Patients were 
classified as receiving GCCP or guideline inconsistent CINV prophylaxis (GICP) if 
they were given or not the recommended drugs daily, respectively (8).  
 
Data analysis 
Descriptive statistics were adopted. Intensity of the nausea was measured over 24 
hours and expressed as the median and Inter-Quartile Ranges (IQR), and the 
episodes of VR were expressed as sums. Categorical variables were summarised as 
sums and percentages, and Fisher’s exact test was used for comparisons. 
 A correlation structure was specified to account for repeated measures over time 
(24, 48, 72, 96 and 120 hours after reinfusion) on the same patient. A continuous-
time autoregressive of order 1 correlation structure resulted in the best model fit, 
based on Akaike Information Criterion. We controlled by age, sex, treatment and 
number of stem cell bags infused. The linear relationship of nausea intensity over 
time was assessed using restricted cubic splines and was tested with a Wald chi-
square test. The data were analysed with R version 2.15 (20). All p-values are two-
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sided, and a p-value of less than 0.05 was considered significant. 
 
Results 
Over 60% (n = 43) of patients were male, and approximately 80% (n = 56) had HEC. 
More than half (n = 32) of HEC patients were given a high dose melphalan, whereas 
all MEC patients were given melphalan at a lower dose. The patient characteristics 
and treatments administered are shown in table 1.  
 All patients, except one, received methylprednisolone 125 mg on the transplant 
day. Before reinfusion, hydrocortisone 200 mg was administered alone in a MEC 
patient and in combination with methylprednisolone in 15 HEC patients.  
 Nearly all the patients (93%) received 5HT3-RA. Overall, less than 20% received a 
guideline-recommended antiemetic prophylaxis. Only seven HEC patients received 
aprepitant, and one patient alone received dexamethasone. No HEC-patients were 
given prophylactic treatment that was adherent to the MASCC guidelines. In 
contrast, all MEC patients, except one, received post-chemotherapy prevention for 
delayed CINV with a 5HT3-RA (table 1). Two or more antiemetic agents were 
administered to 12 (17%) patients. 
 At the end of the transplant, 51 patients (74%) reported no nausea, 10 reported 
controlled nausea and 7 reported uncontrolled nausea (information missing for 1 
patient). 
 The course of nausea was similar for HEC and MEC patients, which started to 
increase on the second day after reinfusion, peaked between 72 and 96 hours, and 
decreased on the fifth day. Longitudinal regression analyses showed an average 
increase of 3.8 points in nausea intensity every 24 hours.  
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 The overall pattern for vomiting was similar, while retching episodes remained 
unchanged after the third day following transplant. The results are summarised in 
table 2. 
 During the 5-day observation period, 52 (75%) patients reported nausea and over 
60% reported (n=44) vomiting or retching. At least once in the 5 days after 
transplant, 24 patients (35%) had uncontrolled nausea and 40% (n = 28) had more 
than two episodes of vomiting or retching. Overall, 32 patients had NV or retching. 
However, 9 patients experienced emesis or retching without nausea, and 18 (26%) 
experienced nausea without vomiting or retching. At least once, 41 HEC (73%) and 
11 MEC (85%) patients reported nausea, which was uncontrolled in 19 (34%) HEC 
and in five (38%) MEC patients. Similarly, 36 (64%) HEC and 8 (62%) MEC patients 
reported emetic episodes (table 3). More MEC patients reported uncontrolled 
vomiting or retching compared to HEC patients (7, 54% vs 21, 38%), but the emetic 
episodes per day per patients between the two groups were similar (1.2 vs 1.3). 
 However, no significant differences were found between the HEC and MEC 
patients (table 3).  
 Of 12 patients treated with GCCP, 9 (75%) reported no uncontrolled vomiting or 
retching episodes vs 32 (56%) in the GICP group, whereas no difference was 
observed in the control of nausea between patients exposed or not to the 
recommended prophylaxis. However differences were not significant (p = 1.000, data 
not shown). 
 
Discussion  
This study described the course of NV over the five days following auto-HCT. About 
65% of the patients had multiple myeloma and almost all received auto-HCT with 
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melphalan, that is the treatment of choice in patients younger than 65 years 
according to a recent consensus statement (21).  
 We observed a greater incidence of delayed NV compared with previous studies 
(6,7), possibly due to a longer observation period after the end of the conditioning 
regimen (7 days vs 5 days) (22,23). Similar to other studies (22,23), we found no 
significant differences in delayed nausea between HEC and MEC patients. Both 
studies (22,23) showed that HEC patients had a higher risk of delayed emesis, while 
no differences were observed in our study for vomiting and retching. However, our 
MEC subgroup was limited in size and the study did not have enough power for this 
analysis. 
 The clinical course of delayed CINV described in this study differs from that 
portrayed by Bloechi-Daum et al. (22) in their prospective study on 298 naïve 
patients with different cancers. They showed NV plateauing between days 2 and 3 
after chemotherapy and slightly decreasing between day 3 and 4. However, we 
found the peak on day 6 after the end of the conditioning regimen, with an almost 
50% decrease in the nausea intensity on day 7. However, they only included patients 
receiving single-day chemotherapy, while 35% of our patients received multiple-day 
chemotherapy, which may explain the delay in reaching the peak. 
 Our findings highlight the importance of a separate assessment for vomiting and 
retching because their pathways most likely differ. Vomiting decreased along with 
nausea, whereas retching remained significantly unchanged when patients had no 
more matter to expel. Hence, routine assessment of retching may avoid the risk of 
underestimating the adverse chemotherapy effects. However, 40% of our patients 
complained of nausea without emesis or vice versa, confirming that the 
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neurotransmitter pathways of NV are most likely not identical in spite of NV are 
correlated and their clinical course is similar.  
 The poor adherence to guidelines for delayed antiemetic prophylaxis limited to 
HEC patients was already shown in other studies: according to Gomez et al. (11), 
appropriate administration of NK1-RA was approximately 10%. In addition, 
dexamethasone was almost never administered, similar to previous studies 
(8,11,12,24) where administration of corticosteroids ranged between 10-97% of 
patients, depending on the emetogenic potential of chemotherapy and the line of 
treatment. However, immunosuppressed transplant patients are at higher risk of 
infections and steroids were most likely not used to avoid increasing this risk. This 
may explain the overuse of serotonin antagonists and the higher adherence to the 
guidelines in MEC regimens compared with HEC regimens because 5HT3-RAs 
represent an alternative to dexamethasone for delayed CINV only in MEC-treated 
patients. The differences in nausea, vomiting and retching between GCCP and GICP 
patients cannot be commented as information about the antiemetic regimens as well 
as the control of CINV during the acute phase was not collected in the main study. 
The current antiemetic guidelines are aimed only at emesis prevention, and ours as 
well as Aapro’s findings (8), suggest that NV are separate phenomena requiring 
different remedies. However, other causes, such as mucositis, the preliminary 
symptoms of which are nausea and abdominal cramps, may have contributed to the 
increased incidence of NV(25).   
 These exploratory data analyses were limited by the small sample, which did not 
allow subgroup comparisons, and antiemetic doses were not recorded. Moreover, 
the etiology of NV in HCT recipients is multi-factorial and includes damage to the 
gastrointestinal lining that may result in a continual source of serotonin release, side 
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effects of prophylactic antibiotics and narcotic analgesics, and the high-dose 
preparative regimens that lead to a poor end-of-regimen control rate. However, this 
study contributes to our knowledge of the course of NV and retching in transplant 
patients who are usually heavily treated and receive multi-days chemotherapy 
regimens.  
 In summary, delayed CINV continues to be a challenge for healthcare 
professionals working with auto-HCT patients despite the progress in antiemetic 
prophylaxis. In auto-HCT patients, the course of NV differs from other patients 
receiving chemotherapy, with a delayed peak most likely due to multi-drug regimens. 
Further studies are warranted to define the best anti-emetic regimen in this 
population and to explore the control of symptoms in auto-HCT patients treated with 
GCCP compared to GICP.  
 Finally, nausea and vomiting were confirmed being two separate entities. 
Similarly, the retching was shown as a symptom different from vomiting. As not only 
vomiting but also nausea and retching create discomfort to the patients and impact 
on their quality of life, all of the three symptoms should be assessed, prevented, and 
treated separately in the routine clinical practice.     
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Table 1 Patients’ characteristics 
 All patients (n=69) HEC (n=56)a MEC (n=13)b 
Male (n,%) 
Age years (median; IQR) 
Diagnosis (n) 
MM/LNH/L. Plasmacellular/Otherc 
Antiemetic prophylaxis (n)d  
5-HT3RA 
Metoclopramide 
APR 
Chlorpheniramine 
Alizapride 
DEX  
GCCP (n,%) 
43 (62) 
58 [50.5-62.5] 
 
45/10/5/9 
 
64 
9 
7 
3 
1 
1 
12 (17.4) 
34 (61) 
57.5 [49-62] 
 
33/10/5/8 
 
52 
8 
7 
3 
1 
1 
- 
9 (69) 
62 [57-64.5] 
 
12/-/-/1 
 
12 
1 
- 
- 
- 
- 
12 (92.3) 
APR, aprepitant; BEAM, bendamustine-etoposide-cytarabine-melphalan; Bu-Cy, busulfan-
cyclophosphamide; DEX, dexamethasone; D-PACE, dexamethasone-cisplatin-adriblastin-
cyclophosphamide-etoposide; FEAM, fotemustine-etoposide-cytarabine-melphalan; 5-HT3RA, 5-
hydroxytryptamine receptor antagonist; LH, Hodgkin’s lymphoma; NHL, Non-Hodgkin’s lymphoma; 
LAM, acute myeloid leukemia; MM, multiple myeloma; M-VD, velcade-melphalan-dexamethasone. 
a Melphalan 200 mg/m2 (n=32), FEAM (n=14), M-VD (n=4), Bu-Cy (n=3), Ara-C/Idarubicin (n=1), 
BEAM (n=1), D-PACE (n=1)  
b All patients received Melphalan 100 mg/m2 
c LAM (n=4), LH (n=2), L. Burkitt (n=1), Reticulosarcoma (n=1) in HEC group. M. Waldestrom (n=1) 
in MEC group 
d The sum is greater than the total because some patients received multidrug treatment 
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Table 2 Nausea, vomiting and retching over the five days following autologous transplant 
 Time following the transplant day 
0-24 h 24-48 h 48-72 h 72-96 h 96-120 h 
Daily nausea intensitya 
(median [IQR]) 
HEC (n=56) 
MEC (n=13) 
All (n=69) 
 
 
2.8 [0-12.5] 
0 [0-10.5] 
0.4 [0-12.1] 
 
 
4 [0-16.7] 
0 [0-13.2] 
1.7 [0-16.3] 
 
 
7.1 [0-20] 
8.3 [0.5-35.2] 
7.2 [0-20.9] 
 
 
9.2 [0-30.8] 
12 [0-44.5] 
10 [0-31.5] 
 
 
6.1 [0-24.7] 
4.9[0-31.3] 
5.7 [0-24.3] 
Patients with controlled, 
uncontrolled or no nausea 
(n) a,b 
HEC (n=56) 
MEC (n=13) 
All (n=69) 
 
 
 
13/9/34 
3/1/9 
16/10/43 
 
 
 
16/10/30 
3/2/8 
19/12/38 
 
 
 
22/12/22 
4/4/5 
26/16/27 
 
 
 
20/16/20 
3/4/6 
23/20/26 
 
 
 
18/12/26 
4/3/6 
22/15/32 
Vomiting episodes (N) 
HEC (n=56) 
MEC (n=13) 
All (n=69) 
 
20 
6 
26 
 
29 
2 
31 
 
73 
9 
82 
 
51 
8 
59 
 
33 
10 
43 
Retching episodes (N)  
HEC (n=56) 
MEC (n=13) 
All (n=69) 
 
15 
1 
16 
 
29 
9 
38 
 
35 
11 
46 
 
36 
11 
47 
 
35 
13 
48 
Patients with controlled vs 
uncontrolled vomiting or 
retching or none (n)c 
HEC (n=56) 
MEC (n=13) 
All (n=69) 
 
 
 
6/4/46 
2/1/10 
8/5/56 
 
 
 
5/10/41 
3/1/9 
8/11/50 
 
 
 
12/14/30 
3/3/7 
15/17/37 
 
 
 
13/14/29 
1/2/10 
14/16/39 
 
 
 
10/14/32 
3/2/8 
13/16/40 
a On Numeric Rating Scale  0-100 
b No nausea (NRS <5)/controlled (NRS 5-25)/uncontrolled (>25) 
c Controlled (≤ 2 episodes)/uncontrolled (>2 episodes) 
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Table 3 Nausea, vomiting and retching over the five days in HEC and MEC patients 
 
HEC (n=56) 
N (%) 
MEC (n=13) 
N (%) 
pd 
At least one episode of  
any nauseaa 
uncontrolled nauseab  
 
41 (73) 
19 (34) 
 
11(85) 
5 (38) 
 
1.000 
1.000 
At least one episode of  
vomiting or retching 
uncontrolled vomiting or retchingc 
 
36 (64) 
21 (38) 
 
8 (62) 
7 (54) 
 
1.000 
1.000 
a > 5 on NRS  
b > 25 on NRS  
c > 2 episodes 
d Fisher’s exact test 
 
